CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

 

Begin main content

Reports

We found 7059 result(s)

CADTH COVID-19 Webinar - Community-Based Aerosol Transmission Of COVID-19 and HVAC Systems

Event Date: December 3, 2020
Result type: Events

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which causes COVID-19, spreads when an infected person breathes out, sneezes, coughs, or talks, thus putting virus-carrying liquid particles into the air where they can infect other people. Larger particles fall to the ground rapidly, while smaller particles, sometimes called aero...

emicizumab (Hemlibra)

Last Updated: December 1, 2020
Result type: Reports
Product Line: Reimbursement Review
Generic Name: emicizumab
Indications: Indicated for hemophilia A (congenital factor VIII deficiency) patients with or without factor VIII inhibitors as routine prophylaxis to prevent bleeding or reduce the frequency of bleeding episodes. There is limited clinical experience of Hemlibra use in patients with mild or moderate hemophilia A.

  • Brand Name: Hemlibra
  • Manufacturer: Hoffmann-La Roche Ltd.
  • Project Number: ST0651-000
  • Project Status: Active
  • Submission Type: Initial

ozanimod (Zeposia)

Last Updated: December 1, 2020
Result type: Reports
Product Line: Reimbursement Review
Generic Name: ozanimod
Indications: For the treatment of patients with relapsing remitting multiple sclerosis (RRMS) to decrease the frequency of clinical exacerbations.

  • Brand Name: Zeposia
  • Manufacturer: Celgene Inc.
  • Project Number: SR0652-000
  • Project Status: Active
  • Submission Type: Initial

durvalumab (Imfinzi)

Last Updated: December 2, 2020
Result type: Reports
Product Line: Reimbursement Review
Generic Name: durvalumab
Indications: IMFINZI in combination with etoposide and either carboplatin or cisplatin is indicated for the first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC).

  • Brand Name: Imfinzi
  • Manufacturer: AstraZeneca Canada Inc.
  • Project Number: PC0234-000
  • Project Status: Received
  • Submission Type: Initial

vedolizumab (Entyvio)

Last Updated: November 27, 2020
Result type: Reports
Product Line: Reimbursement Review
Generic Name: vedolizumab
Indications: For the treatment of adult patients with moderately to severely active Crohn’s disease who have had an inadequate response with, lost response to, or were intolerant to immunomodulators or a TNFα antagonist; or have had an inadequate response, intolerance, or demonstrated dependence on corticosteroids.

  • Brand Name: Entyvio
  • Manufacturer: Takeda Canada Inc.
  • Project Number: SR0647-000
  • Project Status: Active
  • Submission Type: Initial

pembrolizumab (Keytruda)

Last Updated: December 1, 2020
Result type: Reports
Product Line: Reimbursement Review
Generic Name: pembrolizumab
Indications: ​For the first line treatment of adult patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer (CRC)

  • Brand Name: Keytruda
  • Manufacturer: Merck Canada Inc.
  • Project Number: PC0235-000
  • Project Status: Received
  • Submission Type: Initial

larotrectinib (Vitrakvi)

Last Updated: December 1, 2020
Result type: Reports
Product Line: Reimbursement Review
Generic Name: larotrectinib
Indications: For the treatment of adult and pediatric patients with solid tumours that: have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion without a known acquired resistance mutation; are metastatic or where surgical resection is likely to result in severe morbidity, and; have no satisfactory treatment options.

  • Brand Name: Vitrakvi
  • Manufacturer: Bayer Inc.
  • Project Number: PC0221-000
  • Project Status: Active
  • Submission Type: Resubmission